GenSight Biologics Reports Interim Financial Results for the First Half of 2017

Paris, France, July 28, 2017 – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME
eligible), a biopharma company that discovers and develops innovative gene therapies for
neurodegenerative retinal diseases and diseases of the central nervous system, today announced its
interim financial results for the first half of 2017. The full interim financial report is available on the
Company’s website in the Investors section. The 2017 half-year financial statements were subject to a
limited review by the Company’s statutory auditors, and approved by the Board of directors on July 27,
2017.

Selected financial information (IFRS)
In million euros H1 2016 H1 2017
Operating income 1.9 2.0
Research and development expenses (8.6) (7.7)
General and administrative expenses (2.6) (4.4)
Operating profit (loss) (9.3) (10.1)
Net profit (loss) (9.3) (10.1)
EPS (in € per share) (0.68) (0.51)
Net cash flows from operating activities (10.8) (11.2)
Net cash flows from investment activities (0.1) 0.0
Net cash flows from financing activities – 20.8
Net cash flows (11.0) 9.6
Cash and cash equivalents at closing 19.1 63.6

The Company’s operating income increased by 6.1% from €1.9 million in the first half of 2016 to €2.0
million in the first half of 2017. This income was essentially in the form of research tax credit (Crédit Impôt
Recherche).

Research and Development expenses decreased by 10.5% from €8.6 million in the first half of 2016 to
€7.7 million over the same period in 2017. This decrease is solely due to a non-recurring milestone
payment in 2016 in connection with one of the Company’s license agreements.
General and administrative expenses increased by 68.8% from €2.6 million to €4.4 million over the
period, primarily as a result of non-cash share-based compensation expenses related to equity grants to
employees in the second half of 2016. Excluding these non-cash expenses, general and administrative
expenses increased by 47.8%, reflecting the strengthening of GenSight’s administrative and management
functions as a listed company.

The Company’s net loss for the first half of 2017 amounted to €(10.1) million compared with €(9.3) million
a year earlier. The loss per share (based on the weighted average number of shares outstanding over the
period) amounted to €(0.51) and €(0.68) for the first halves of 2017 and 2016, respectively.

Net cash flows from operating activities in the first halves of 2017 and 2016 were €(11.2) million and
€(10.8) million, respectively, relatively stable over the period.
Net cash flows from financing activities amounted to €20.8 million in the first half of 2017, primarily as
a result of the net proceeds of the Company’s capital increase in June 2017.
GenSight Biologics will report its cash position as of September 30, 2017 on October 26, 2017.

Source: www.gensight-biologics.com